Protagonist Therapeutics Inc PTGX:NASDAQ

RT Quote | Last NASDAQ LS, VOL From CTA | USD
after hours iconAfter Hours: Last | 04/18/24 EDT
25.22UNCH (UNCH)
Volume
71,114
Close
25.22UNCH (UNCH)
Volume
363,037
52 week range
13.72 - 33.34
Loading...
  • Open25.34
  • Day High25.75
  • Day Low25.17
  • Prev Close25.57
  • 52 Week High33.34
  • 52 Week High Date03/01/24
  • 52 Week Low13.72
  • 52 Week Low Date10/25/23

Key Stats

  • Market Cap1.47B
  • Shares Out58.28M
  • 10 Day Average Volume0.57M
  • Dividend-
  • Dividend Yield-
  • Beta2.07
  • YTD % Change9.99

KEY STATS

  • Open25.34
  • Day High25.75
  • Day Low25.17
  • Prev Close25.57
  • 52 Week High33.34
  • 52 Week High Date03/01/24
  • 52 Week Low13.72
  • 52 Week Low Date10/25/23
  • Market Cap1.47B
  • Shares Out58.28M
  • 10 Day Average Volume0.57M
  • Dividend-
  • Dividend Yield-
  • Beta2.07
  • YTD % Change9.99

RATIOS/PROFITABILITY

  • EPS (TTM)-1.47
  • P/E (TTM)-17.18
  • Fwd P/E (NTM)64.67
  • EBITDA (TTM)-92.675M
  • ROE (TTM)-28.59%
  • Revenue (TTM)60.00M
  • Gross Margin (TTM)-
  • Net Margin (TTM)-131.59%
  • Debt To Equity (MRQ)-

EVENTS

  • Earnings Date05/02/2024(est)
  • Ex Div Date-
  • Div Amount-
  • Split Date-
  • Split Factor-

Latest On Protagonist Therapeutics Inc

 

Profile

MORE
Protagonist Therapeutics, Inc. is a biopharmaceutical company. The Company uses its peptide-based chemical entities rusfertide and JNJ-2113 in different stages of development, all derived from its proprietary discovery technology platform. The Company’s clinical programs fall into two categories of diseases: hematology and blood disorders, and inflammatory and immunomodulatory diseases. Its lead clinical asset, rusfertide (PTG-300), is an injectable hepcidin mimetic in...
Harold Selick Ph.D.
Independent Chairman of the Board
Dinesh Patel Ph.D.
President, Chief Executive Officer, Director
Asif Ali
Chief Financial Officer, Executive Vice President
Address
7707 Gateway Blvd Ste 140
Newark, CA
94560-1160
United States

Top Peers

SYMBOLLASTCHG%CHG
AGIO
Agios Pharmaceuticals Inc
29.43UNCHUNCH
EWTX
Edgewise Therapeutics Inc
15.45UNCHUNCH
RCUS
Arcus Biosciences Inc
14.84UNCHUNCH
AKRO
Akero Therapeutics Inc
20.51UNCHUNCH
INBX
Inhibrx Inc
34.45UNCHUNCH